Introduction {#s0005}
============

Hypertension in patients with renal failure is of major importance because it increases the susceptibility to renal and cardiovascular diseases. Renal ischaemia-reperfusion (RIR) is an important cause of renal dysfunction, and renal injury may occur after surgical procedures involving transient renal aortic occlusion [@b0005]. Renal hypoxia and ischaemia can lead to renal hypertension-induced dysfunction in animal models, through activation of the renin-angiotensin aldosterone system (RAAS). Reactive oxygen species (ROS)-mediated cellular damage can be expected to occur when the oxygen is supplied to the tissue by reperfusion and ROS formation exceeds the high cellular detoxification capacity of the kidneys [@b0010]. Chatterjee and Thiemermann [@b0015] reported that the RIR model is an experimental model of acute renal failure, where progressive vascular dysfunction is the main reason for the later alterations in the kidney, with angiotensin-converting enzyme and ROS playing the central role. RIR injury is mediated through an acute inflammatory response characterised by activation of peripheral blood mononuclear cells and neutrophils, which release reactive oxygen metabolites and cytotoxic proteins. It accompanies renal injury, which is generally associated with increased microvascular permeability, interstitial oedema, impaired vasoregulation, inflammatory cell infiltration, parenchymal cell dysfunction, necrosis and loss of cell volume [@b0020].

Flaxseed (*Linum usitatissimum* Linn.) belongs to the family Linaceae, and is commonly known as linseed. Secoisolariciresinol diglucoside (SDG) is the main lignan isolated from flaxseed. The SDG content of flaxseed is ≈16.4 mg/g in de-fatted flaxseed meal [@b0025]; SDG has been isolated in pure form [@b0030], and is reported to be a phytoestrogen. Phytoestrogens from dietary soy have been reported to have antihypertensive potential [@b0035; @b0040]. Prasad [@b0025] reported that SDG is a long-acting hypotensive agent, with its activity due to stimulation of guanylate cyclase activity. The objectives of the present study were to evaluate the effect of an ethanolic extract of *L. usitatissimum* (EELU) on haemodynamic and renal function in RIR injury in rats.

Materials and methods {#s0010}
=====================

Authenticated seeds of *L. usitatissimum* (variety NL-97) were obtained from Dr. P.B. Ghorpade (Principal Scientist and Linseed breeder, Punjabrao Deshmukh Krushi Vidyapeeth, College of Agriculture, Nagpur, India, Maharashtra State, India) and a vouched specimen was deposited at the institute.

Adrenaline hydrochloride, superoxide dismutase (SOD) and malondialdehyde (MDA) were obtained from Sigma Chemical Co. (St Louis, MO, USA). Reduced glutathione (GSH), 5,5′-dithiobis(2-nitro-benzoic acid) and thiobarbituric acid were obtained from Hi Media, India. All chemicals used were of analytical grade.

The seeds of *L. usitatissimum* were processed for extraction of lignan-concentrated EELU by the method of Eliasson et al. [@b0045] and extraction of oil at our omega-3-oil unit (Sangamner, Maharashtra, India; set up under National Agriculture Innovation Project funded by Indian council of Agricultural Research, New Delhi, India). The double cold-pressed flaxseed cake/meal obtained from this oil unit was de-fatted by *n*-hexane in a soxhlet apparatus to remove residual oil. The de-fatted cake was then hydrolysed with 1 m aqueous sodium hydroxide for 1 h at room temperature with intermittent shaking, followed by extraction with 50% ethanol. The filtrate was acidified to pH 3 using 1 m hydrochloric acid. The filtrate was dried on a tray dryer at 50 °C. The yield of dry powder was 14.81% w/w. A weighed quantity of EELU was dissolved in distilled water to prepare the different doses for pharmacological studies. The analysis of EELU samples by high-performance thin-layer chromatography was reported earlier by Zanwar et al. [@b0050]. The SDG lignan content in flax lignan concentrate extracted from the seeds was 40 mg/g.

Male Wistar rats (200--250 g) were purchased from National Toxicology Centre, Pune, India. Rats were housed in an air-conditioned room at 22 ± 2 °C, relative humidity 45--55% and 12-h light: 12-h dark cycle. The rats had free access to standard food pellets (Chakan Oil Mills, Pune, India) and water was freely available. The experimental protocol was approved by the Institutional Animal Ethics Committee constituted in accordance with the rules and guidelines of the Committee for the Purpose of Control and Supervision on Experimental Animals, India.

The rats were anaesthetised with thiopental sodium (35 mg/kg, intraperitoneal) on day 0. The abdominal region was shaved and the right kidney removed through a small flank incision. After 2 weeks of recovery the nephrectomised rats were divided into four groups of eight each. In the sham group (group I) the left renal artery was exposed but not subjected to RIR. In the RIR groups (groups II--IV) a small incision was made on the left side of peritoneal cavity of the nephrectomised rat to expose the left kidney. The left renal artery was occluded for 45 min by using a bulldog clamp; the clamp was removed and the kidney reperfused for 4 weeks. In groups I and II, rats received saline treatment for 4 weeks. Group III rats received EELU 200 mg and in group IV, EELU 400 mg, administered once daily by oral gavage for 4 weeks after RIR.

To assess haemodynamic changes, the rats were anaesthetised with urethane (1.25 g/kg, intraperitoneal) and the haemodynamic changes measured using a polyethylene cannula (PE 50) filled with heparinised saline (100 IU/mL) inserted into the right carotid artery. The cannula was connected to a transducer and the signal amplified using a bioamplifier. The left ventricular systolic blood pressure (SBP) was measured using a microtip transducer catheter (Model SRP-320, Millar Instrument, Inc, Houston, TX, USA) inserted into the left ventricle via the right carotid artery and connected to a bioamplifier. The heart rate, maximum first derivative of ventricular pressure (dp/dt max), minimum first derivative of ventricular pressure (dp/dt min) and left ventricular end-diastolic pressure (EDP) were obtained from primary signals (left ventricular SBP and blood pressure) using a data-acquisition system (AD Instruments Pty. Ltd., with LABCHART 6 software, Bella Vista, NSW, Australia).

Blood was collected from the rats (six) by retro-orbital puncture after 4 weeks of reperfusion and centrifuged at 10,000*g* for 15 min at 4 °C. Serum was isolated and used to estimate blood urea nitrogen (BUN) using Jaffe's method, and creatinine (DAM method) with a standard diagnostics kits (Span Diagnostics, Gujarat, India). On the last day, rats were housed in metabolic cages for 24 h and urine flow was measured.

After haemodynamic measurement the left kidney of each rat was isolated, weighed and two samples were randomly selected for histopathology. The left kidney of the remaining six rats was cut into four portions; one was individually homogenised and centrifuged. The clear supernatant was collected after centrifugation and used for the assays of endogenous antioxidant enzymes. SOD was determined by the method of Misra and Fridovich [@b0055].

GSH, glutathione S transferase (GST) and glutathione peroxidase (GP*x*) were determined by the method of Moron et al. [@b0060], Habig et al. [@b0065] and Rotruck et al. [@b0070], respectively. Lipid peroxidation (MDA) formation was estimated by the method of Slater and Sawyer [@b0075]. The sediment was resuspended in ice cold Tris buffer (10 mm, K^+^, pH 7.4) and was used to estimate membrane-bound enzymes. Na^+^K^+^-ATPase and Mg^2+^-ATPase were assayed according to the methods of Bonting [@b0080] and Ohnishi et al. [@b0085], respectively. The inorganic phosphorus was estimated by the method of Fiske and Subbarow [@b0090]. Total proteins were determined by the method of Lowry et al. [@b0095].

Myeloperoxidase (MPO) activity was measured in renal tissue (six rats) by a procedure similar to that previously documented by Krawisz et al. [@b0100]. The renal homogenate levels of TNF-α were determined in renal tissue (six rats) with an ELISA (Thermoscientific, rat TNF-α kit, Cat. number-ER3TNFA. Pierce Biotech Int., Rockford, IL, USA) according to the manufacturer's instructions.

To assess DNA fragmentation, genomic DNA was extracted from renal tissue (two rats) using the phenol--chloroform C-TAB method; 10 μg of DNA were loaded onto 1.5% agarose gel and DNA electrophoresis carried out at 80 V for 1--2 h. The gel was stained with ethidium bromide 0.5 mg/mL and examined under an ultraviolet transilluminator for the presence of the amplified DNA. The image of the gel was captured using a gel documentation instrument.

For flow-cytometric analysis of cellular necrosis and viability from kidney, a single-cell suspension from renal tissue (six rats) of each rat was prepared by the trypsinization method. Briefly, renal tissue was extensively perfused *in situ* in PBS to remove blood, and irrigated in a buffer containing Hepes (10 mm), KCl (3 mm), NaCl (130 mm), NaH~2~PO~4~--H~2~O (1 mm), and glucose (10 mm, pH 7.4). The renal tissue was homogenised and suspended in Hanks balanced salt solution. Renal tissue homogenate was then treated with trypsin for 10 min and trypsin inhibitor for 5 min. The cell suspension was obtained by passing the trypsinised renal tissue through a nylon mesh, washed with cold PBS, and then re-suspending in 1× binding buffer at a concentration of 1--2 × 10^6^ cells/mL. An aliquot of 100 μL of cell suspension was transferred to a Falcon tube and 10 μL of propidium iodide (PI) probe was added (Sigma). The cell suspension was mixed thoroughly and incubated for 15 min in the dark at room temperature (25 °C). Data were acquired and analysed in the processed samples by flow cytometry using CELLQuest software (Becton & Dickinson, San Diego, CA, USA) [@b0105].

For the histological evaluation by haematoxylin and eosin (H&E) staining, kidney (two rats) samples from each group were cut into small pieces in 4% buffered paraformaldehyde solution and embedded in paraffin. Sections (3--4 μm) were cut by microtome and passed through various grades of ethanol. Sections were stained with H&E then dehydrated through graded ethanol, cleared in xylene and mounted with DPX (Fluka, Switzerland). The stained sections were graded for the presence of medullary congestion, tubular cell necrosis and dilation, cytoplasmic vacuolization, nuclear pyknosis, and cytoplasmic eosinophilia, according to the following scale: 0, no occurrence; I, 0--25% present; II, 25--50% present; and III, \>50% present.

Data are expressed as the mean (SEM) and analysed statistically by one-way anova followed by the *post hoc* Dunnett's test; differences with *P *\< 0.05 were considered statistically significant.

Results {#s0015}
=======

In the nephrectomised and RIR group after 4 weeks there were significant changes in haemodynamic variable. The heart rate, SBP, diastolic (DBP), mean arterial blood pressure (MABP), EDP, dp/dt max, dp/dt min, exponential *τ* and pressure--time index were increased significantly. EELU (400 mg/kg) treatment showed a significant decrease in SBP, DBP, MABP, EDP, dp/dt max (all *P *\< 0.001), dp/dt min (*P *\< 0.05), exponential *τ* (*P *\< 0.001) and pressure--time index (*P *\< 0.001). The load-independent index of contractility was significantly decreased in Group II; in Groups III and IV it was significantly higher (*P *\< 0.05 and *P*\<0.001, respectively) than in group II ([Table 1](#t0015){ref-type="table"}).

After 4 weeks, rats in group II had a significantly greater kidney weight and urine flow (*P *\< 0.001, respectively) than rats in group I, whereas rats treated with EELU 400 mg/kg had significantly lower kidney weight (*P *\< 0.05) and urine flow (*P *\< 0.001) than in group II. Both serum creatinine and BUN in group II were significantly greater (*P *\< 0.001) than in group I. However, the creatinine and BUN levels in group IV were significantly (*P *\< 0.001 and *P* \< 0.01, respectively) lower than in group II ([Table 1](#t0015){ref-type="table"}).

MPO activity was significantly increased in the renal tissue homogenate of group II, whereas group IV showed a significant decrease in MPO activity (*P *\< 0.05). The TNF-α level was significantly increased in group II, whereas in group IV it was significantly decreased (*P *\< 0.05; [Table 1](#t0015){ref-type="table"}).

After 4 weeks, rats in group II had a significant decrease in the levels of SOD, GSH, GST and GP*x*, but rats in group IV had significant restoration of the levels of SOD (*P *\< 0.05), GSH (*P *\< 0.01), GP*x* (*P *\< 0.01) and GST (*P *\< 0.01). MDA levels in group II increased significantly (*P *\< 0.01) whereas rats in group IV had significantly lower levels (*P *\< 0.05) than in group II.

The levels of the renal membrane-bound enzymes Na^+^K^+^-ATPase and Mg^2+^-ATPase in group II decreased significantly (both *P *\< 0.01) but rats in group IV had significant restoration in the levels of these enzymes (both *P *\< 0.05).

DNA fragmentation in renal tissue was analysed with agarose-gel electrophoresis. In group II there was intra-nucleosomal DNA damage, in the form of typical fragmentation laddering, which indicates cell apoptosis ([Fig. 1](#f0005){ref-type="fig"}, lane B), whereas there was less DNA fragmentation in groups III and IV ([Fig. 1](#f0005){ref-type="fig"}, lanes C and D, respectively) suggesting anti-apoptotic activity preventing cell death during RIR-induced renal hypertension.

Cellular necrosis in group II was increased significantly (*P *\< 0.001) whereas groups III and IV had a significant (both *P *\< 0.001) decrease in cellular necrosis. The viability of renal cells was significantly (*P *\< 0.001) decreased in group II and significantly (*P *\< 0.001) greater in groups III and IV than in group II ([Fig. 2](#f0010){ref-type="fig"}).

Histological evaluation of the kidney in group I showed regular morphology of renal parenchyma with well-defined glomeruli and tubuli. Rats in group II showed severe (\>50% area of the kidney) vascular congestion, tubular cell necrosis, cytoplasmic vacuolization and nuclear pyknosis. In groups III and IV, despite the presence of mild (0--25% area of the kidney) vasocongestion and tubular cell necrosis, the glomeruli maintained a better morphology than in group II ([Fig. 3](#f0015){ref-type="fig"}).

Discussion {#s0020}
==========

The occlusion of renal artery for 45 min followed by reperfusion results in RIR-mediated renal damage [@b0010; @b0110; @b0115]. RIR can arise as enhanced oxidant stress and possibly the activation of the RAAS [@b0120]. Aunapuu et al. [@b0010] reported that hypertension is the major factor determining progression of acute renal diseases, and showed an increase in SBP after 4 weeks of RIR. In the present study EELU treatment at 400 mg/kg was associated with a significant decrease in SBP, DBP, MABP, EDP, dp/dt max and dp/dt min after 4 weeks of RIR in nephrectomised rats. The antihypertensive activity of SDG was studied by Prasad [@b0025], who reported that SDG is a long-acting hypotensive agent in normotensive rats, and hypothesised that hypotensive activity might be due to stimulation of guanylate cyclase activity (an action similar to that of nitric oxide). These findings support our assumption and explain our results.

It was reported that the kidneys appear to be hypertrophic and their weight is increased after 24 h and 4 weeks of RIR injury [@b0010; @b0125]. Our results are in accordance with a previous study [@b0010], and showed a significant increase in kidney weight in group II after 4 weeks of RIR injury. Treatment with EELU 400 mg/kg significantly reduced the hypertrophic growth of the kidney.

The decline in renal function after 4 weeks of RIR was reflected in our results, showing increased urine flow. Several reports showed an increase in renal function indicators such as BUN and creatinine after 4 and 6 h of RIR injury in nephrectomised rats [@b0110; @b0115]. The present study showed a significant increase in the levels of BUN and creatinine after 4 weeks of RIR injury. Increases in serum creatinine and BUN after 4 weeks might be due to the absence of one kidney in addition to RIR injury in the other kidney. Treatment with EELU (400 mg/kg) significantly restored the levels of BUN and creatinine.

Michels et al. [@b0130] reported that the kidney is extremely sensitive to changes in oxygen tension within its complex architecture, making it very prone to hypoxic injury when the renal artery is temporarily occluded. GST, GP*x* and SOD are the most important endogenous antioxidant enzymes, and they are present in high concentrations in kidney cells. GSH scavenges superoxide radicals and protects protein thiol (--SH) groups from oxidation [@b0135]. Our results showed a significant decrease in the levels of SOD, GSH, GST and GP*x*, and increased lipid peroxidation in group II after 4 weeks. Treatment with EELU (400 mg/kg) significantly increased the level of protective antioxidant enzymes and decreased lipid peroxidation. This suggests that EELU 400 mg/kg protects the kidney against RIR-induced injury through its antioxidant role.

There was a significant reduction in the activity of Na^+^K^+^-ATPase and Mg^2+^-ATPase in the renal homogenate of group II after 4 weeks of RIR injury. Decreased activity of Na^+^K^+^-ATPase in renal ischaemia reperfusion might be due to its interaction at the cytoplasmic surface of the basolateral membrane. The decrease in Mg^2+^-ATPase might be due to RIR-induced destruction of renal parenchyma [@b0140]. In group IV there was a significant increase in levels of Na^+^K^+^-ATPase and Mg^2+^-ATPase, which might be due to the ability of EELU to protect the --SH group from oxidative damage through the inhibition of peroxidation of membrane lipids [@b0145].

The process of cellular apoptosis and necrosis has been reported to contribute to extensive cell loss in many pathological states, such as RIR-induced renal failure [@b0150]. Treatment with EELU (400 mg/kg) for 4 weeks was associated with a significant decrease in cellular necrosis, increase in viability of renal cells and reduction in DNA fragmentation after RIR, which indicated prevention of renal cell death by apoptosis. The histopathology in group II showed morphological changes such as severe tubular cell swelling, necrosis, pyknotic nuclei and medullary congestion. In contrast, sections of the kidney of rats in group IV showed preservation of the architectural structure of the kidney, which further supports the protective action of EELU against RIR injury.

EELU at 200 mg/kg had a limited renoprotective role in RIR-induced renal injury when compared with 400 mg/kg. Oral administration of 200 mg/kg EELU significantly reduced urine flow and serum creatinine levels, increased GSH, decreased cellular necrosis, increased renal cell viability and preserved the architectural structure of the kidney after RIR-induced injury. Its effect on the other variables assessed was insignificant when compared with group II. These differences between the doses might be dose-related but further investigations are needed to determine the appropriate renoprotective dose of EELU.

We conclude that treatment with EELU (400 mg/kg) for 4 weeks after RIR significantly decreased blood pressure, dp/dt max, dp/dt min and pressure--time index. EELU decreased kidney weight, urine flow, and creatinine and BUN levels in the nephrectomised rat. EELU also restored MPO activity and TNF-α levels, and attenuated the RIR-induced oxidative damage, as shown by a significant increase in the levels of endogenous antioxidants SOD, GSH, GST and GP*x*, the membrane-bound enzymes Na^+^K^+^-ATPase and Mg^2+^-ATPase, and significant decrease in the level of the lipid peroxidation product, MDA. The anti-apoptotic role of EELU was evident from the decrease in DNA fragmentation. The flow cytometric study confirmed a decrease in cellular necrosis after RIR. The histopathology of kidney provided structural evidence for the renoprotective effect of EELU.
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![Effects of EELU on DNA fragmentation in RIR-induced injury in rats: (A) sham, (B) RIR, (C) EELU 200 mg/kg, (D) EELU 400 mg/kg groups.](gr1){#f0005}

![Effect of EELU on cellular necrosis and viability detected in renal cells by flow cytometry using the PI method; PI fluorescence intensity was measured using FL-1. Representative dot-plot images from four experimental groups: (A) sham, (B) RIR, (C) EELU 200 mg/kg, and (D) EELU 400 mg/kg. A histogram of cellular necrosis (E) and viability (F) were plotted; each bar represents the mean ± SEM of four experimental groups. ^∗∗∗^*P *\< 0.001 vs. RIR group.](gr2){#f0010}

![The effect of EELU treatment on morphological changes assessed by histological examination of the renal cortex of rats by H&E stain (×100). Representative histological images (A) sham group; regular renal tissue with glomeruli (arrow) and tubuli (☆). (B) RIR group, cellular vacuolisation (arrowhead), congestion (arrow), and necrosis (☆); (C) EELU 200 mg/kg, reduced congestion (arrow); and (D) EELU 400 mg/kg showing reduced glomeruli necrosis (arrow) and tubular dilation (☆).](gr3){#f0015}

###### 

Haemodynamic changes and left ventricular function, renal function, and endogenous antioxidant enzymes and membrane-bound phosphatase enzymes.

  Mean (SEM) variable                                       Group                                                                                                                      
  --------------------------------------------------------- ----------------- ---------------------------------------------------- --------------------------------------------------- ----------------------------------------------------
  Heart rate, beats/min                                     340.4 (11.52)     436.1 (19.9[⁎⁎⁎](#tblfn3){ref-type="table-fn"})      373.8 (13.80[\#\#](#tblfn5){ref-type="table-fn"})   360.4 (16.10[+++](#tblfn8){ref-type="table-fn"})
  SBP, mmHg                                                 97.7 (2.4)        132.1 (2.0[⁎⁎⁎](#tblfn3){ref-type="table-fn"})       124.6 (4.2^ns^)                                     119.9 (3.2[+](#tblfn6){ref-type="table-fn"})
  DBP, mmHg                                                 71.16 (1.57)      101.6 (1.15[⁎⁎⁎](#tblfn3){ref-type="table-fn"})      96.63 (2.79[\#](#tblfn4){ref-type="table-fn"})      93.91 (2.77[+](#tblfn6){ref-type="table-fn"})
  MABP, mmHg                                                82.54 (1.32)      118.7 (1.48[⁎⁎⁎](#tblfn3){ref-type="table-fn"})      112.0 (2.87^ns^)                                    108.5 (2.39[++](#tblfn7){ref-type="table-fn"})
  EDP, mmHg                                                 4.30 (0.27)       8.94 (0.40[⁎⁎⁎](#tblfn3){ref-type="table-fn"})       8.53 (0.32^ns^)                                     7.12 (0.57[+](#tblfn6){ref-type="table-fn"})
  Max dp/dt, mmHg/s                                         1212.1 (184.1)    2572.2 (296.1[⁎⁎⁎](#tblfn3){ref-type="table-fn"})    1788.4 (236.6^ns^)                                  1245.1 (160.3[++](#tblfn7){ref-type="table-fn"})
  Min dp/dt, mmHg/s                                         −1433.3 (132.3)   -- 2617.7 (287.6[⁎](#tblfn1){ref-type="table-fn"})   -- 1926.1 (374.4^ns^)                               -- 1511.2 (230.4[+](#tblfn6){ref-type="table-fn"})
  Contractility index                                       18.49 (0.88)      8.64 (0.54[⁎⁎⁎](#tblfn3){ref-type="table-fn"})       12.14 (0.84[\#](#tblfn4){ref-type="table-fn"})      13.73 (1.45[+](#tblfn6){ref-type="table-fn"})
  Exponential *τ*, ms                                       18.40 (0.65)      26.49 (1.08[⁎⁎⁎](#tblfn3){ref-type="table-fn"})      22.51 (0.85[\#](#tblfn4){ref-type="table-fn"})      21.01 (0.99[++](#tblfn7){ref-type="table-fn"})
  Pressure--time index                                      4.62 (0.048)      12.64 (0.71[⁎⁎⁎](#tblfn3){ref-type="table-fn"})      9.89 (1.23^ns^)                                     7.81 (0.87[++](#tblfn7){ref-type="table-fn"})
  *Renal function*                                                                                                                                                                     
  Kidney weight, mg                                         756.0 (19.40)     900.4 (14.19[⁎⁎⁎](#tblfn3){ref-type="table-fn"})     847.8 (19.32^ns^)                                   817.8 (22.77[+](#tblfn6){ref-type="table-fn"})
  Urine flow, μL/min/kg                                     35.66 (1.18)      69.24 (4.29[⁎⁎⁎](#tblfn3){ref-type="table-fn"})      54.19 (3.72[\#](#tblfn4){ref-type="table-fn"})      48.97 (3.65[++](#tblfn7){ref-type="table-fn"})
  BUN, mg/dL                                                19.7 (1.31)       63.8 (8.87[⁎⁎⁎](#tblfn3){ref-type="table-fn"})       47.99 (6.61^ns^)                                    30.7 (2.70[++](#tblfn7){ref-type="table-fn"})
  Serum creatinine, mg/dL                                   1.06 (0.21)       4.08 (0.33[⁎⁎⁎](#tblfn3){ref-type="table-fn"})       2.58 (0.29[\#\#](#tblfn5){ref-type="table-fn"})     1.94 (0.062[+++](#tblfn8){ref-type="table-fn"})
  TNF-α, pg/mL                                              48.7 (13.42)      223.5 (20.53[⁎⁎⁎](#tblfn3){ref-type="table-fn"})     175.4 (18.90^ns^)                                   132.9 (26.29[+](#tblfn6){ref-type="table-fn"})
  MPO, IU/mg protein                                        3.13 (0.43)       10.0 (1.39[⁎⁎](#tblfn2){ref-type="table-fn"})        7.41 (2.16^ns^)                                     4.95 (0.43[+](#tblfn6){ref-type="table-fn"})
  *Enzymes*                                                                                                                                                                            
  SOD, unit/mg protein                                      9.67 (1.30)       3.85 (0.61[⁎⁎](#tblfn2){ref-type="table-fn"})        6.65 (1.65^ns^)                                     8.16 (0.33[+](#tblfn6){ref-type="table-fn"})
  GSH, μg/mg protein                                        31.57 (1.59)      20.67 (1.27[⁎⁎⁎](#tblfn3){ref-type="table-fn"})      26.04 (0.52[\#](#tblfn4){ref-type="table-fn"})      28.47 (1.86[++](#tblfn7){ref-type="table-fn"})
  MDA, nmol/mg protein                                      2.94 (0.08)       4.90 (0.42[⁎⁎](#tblfn2){ref-type="table-fn"})        3.90 (0.37^ns^)                                     3.33 (0.37[+](#tblfn6){ref-type="table-fn"})
  GPx, μmol/min/mg protein                                  24.87 (0.49)      19.67 (1.2[⁎⁎](#tblfn2){ref-type="table-fn"})        21.80 (0.44^ns^)                                    24.60 (1.0[++](#tblfn7){ref-type="table-fn"})
  GST, μmol/min/mg protein                                  146.9 (4.71)      95.8 (6.66[⁎⁎⁎](#tblfn3){ref-type="table-fn"})       110.3 (5.93^ns^)                                    132.7 (6.46[++](#tblfn7){ref-type="table-fn"})
  Na^+^K^+^-ATPase, μmol inorganic P liberated/mg protein   6.41 (0.76)       2.95 (0.60[⁎⁎](#tblfn2){ref-type="table-fn"})        4.15 (0.39^ns^)                                     5.87 (0.70[+](#tblfn6){ref-type="table-fn"})
  Mg^2+^-ATPase, μmol inorganic P liberated/mg protein      10.69 (1.41)      4.75 (0.44[⁎⁎](#tblfn2){ref-type="table-fn"})        7.24 (1.26^ns^)                                     9.86 (1.21[+](#tblfn6){ref-type="table-fn"})

Data were analysed by one-way anova followed by *post hoc* Dunnett's tests, with *P \<* 0.05 considered to indicate significance.

*P \<* 0.05.

*P *\< 0.01.

*P \<* 0.001 vs. sham group.

*P \<* 0.05.

*P *\< 0.01 vs RIR group.

*P *\< 0.05.

*P *\< 0.01.

*P *\< 0.001 vs. RIR group.
